Clinical implications of tamoxifen ocular toxicity

Abstract

Tamoxifen citrate is an anti-estrogen compound that has gained widespread use in breast cancer therapy due to its clinical efficacy and relatively low toxicity. A 48-year-old female being treated for breast cancer developed subtle visual disturbances after receiving 21.9 g of tamoxifen over a 3-year period. This case report reviews tamoxifen-induced ocular toxicity, it's proposed etiology of toxicity, the differential diagnosis for crystalline retinopathy, and stresses the need for routine vision care in these patients.